Research programme: anticancer therapeutics - i2 Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - i2 Pharmaceuticals

Latest Information Update: 08 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator i2 Pharmaceuticals
  • Developer i2 Pharmaceuticals; Sea Lane Biotechnologies
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates
  • Mechanism of Action ERBB-3 receptor modulators; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 May 2017 i2 Pharmaceuticals acquires Surrobodies™ technology from Sea Lane Biotechnologies
  • 23 Jul 2015 Sea Lane biotechnologies has patent protection for the Surrobodies™ technology
  • 23 Jul 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top